Vistagen Therapeutics, Inc. VTGN 深 沪
等待开盘 10-07 09:30:00 美东时间
0.2548
-0.008
-3.19%
华盛通- 最 高0.5476
- 今 开0.2654
- 成交量 122.69万股
- 最 低 0.226
- 昨 收 0.2632
- 总市值 5.27万
- 52周最高 5.14
- 市盈率 静 --
- 换手率 592.71%
- 52周最低 0.198
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 495.00
- 量 比 1.26
- 振 幅 122.19%
- 历史最低 0.198
- 每 手 1
- 风险率 1.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data
Vistagen reports positive preliminary Phase 3 data showing fasedienol nasal spray reduces social anxiety with strong safety results.
09-23 21:25
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
Vistagen's Phase 3 fasedienol trial missed its main endpoint, but the company found a severe-patient signal and plans an FDA meeting.
07-01 01:35
Nasdaq Gains Over 300 Points; Chicago PMI Falls In June
US stocks traded higher, Nasdaq up 150 points. Dow up 0.02%, Nasdaq up 0.68%, S&P 500 up 0.28%. Tech shares surged, real estate stocks fell. Chicago Business Barometer declined to 56.7.
07-01 00:08
US Stocks Mixed; Home Prices Increase 1.1% In April
US stocks mixed, Dow falls 0.2%. Leading sectors: tech up 1%, real estate down 1.4%. S&P 500 up 0.09%. Edible Garden AG up 87%, Unicycive Therapeutics down 46%.
06-30 21:47
VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 15.91 percent increase over losses of $(0.44) per
06-16 05:18
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints
Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pressure on the stock.
03-05 23:38
Vistagen Therapeutics Earnings Report: Q3 Overview
Vistagen Therapeutics (NASDAQ:VTGN) just disclosed its Q3 earnings on Thursday,...
02-13 05:32
Earnings Scheduled For February 12, 2026
Companies Reporting Before The Bell • Ambev (NYSE:ABEV) is estimated to report ...
02-12 19:11
Maxim Group Downgrades Vistagen Therapeutics to Hold
Maxim Group analyst Jason McCarthy downgrades Vistagen Therapeutics (NASDAQ:VTGN) from Buy to Hold.
2025-12-18 04:46
Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study
Vistagen shares plunge after its Phase 3 fasedienol trial for social anxiety failed to meet the primary endpoint, despite favorable safety data.
2025-12-18 01:42
